Nearly three years after Reed Jobs first appeared at TechCrunch Disrupt to introduce his then-fledgling venture firm, a lot has changed — and Jobs would prefer to discuss all of it rather than his famous surname.
Yosemite's Rapid Ascent
When Yosemite launched, biotech was deep in a post-pandemic hangover and the firm was just getting off the ground. Today, the picture looks markedly different:
- A team of 17 people
- A wave of blockbuster drugs losing patent protection in a narrow window, unlocking fresh commercial and R&D opportunities
- AI elevated from a peripheral curiosity to a core part of Yosemite's operating strategy
"I didn't expect Yosemite to be moving this fast," Jobs said.
AI as a Core Engine
Jobs describes AI not as a tool bolted onto Yosemite's workflow, but as deeply embedded in how the firm identifies, evaluates, and supports biotech investments. The convergence of AI capabilities and the looming patent cliff has created what he sees as a rare, compounding opportunity in drug development.
The Patent Cliff Opportunity
Several high-revenue therapeutics are set to lose exclusivity in roughly the same timeframe — a dynamic that historically reshapes competitive landscapes in pharma. For investors and startups alike, it signals open territory for biosimilars, reformulations, and next-generation treatments.
Yosemite appears to be positioning itself squarely at that intersection — where expiring IP meets AI-accelerated drug discovery.
